J Abrams

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741
    J Abrams
    University of Maryland Cancer Center, Baltimore, MD, USA
    J Clin Oncol 17:64-73. 1999
  2. ncbi request reprint Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140
    H L Parnes
    Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, 6130 Executive Plaza EPN Room 2100, Rockville MD 20852, USA
    J Clin Oncol 21:1819-24. 2003
  3. ncbi request reprint Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281
    J Aisner
    University of Maryland Cancer Center, Baltimore, USA
    J Clin Oncol 13:1443-52. 1995
  4. ncbi request reprint Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression
    E M Sotomayor
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Blood 98:1070-7. 2001
  5. ncbi request reprint Loss of nm23 expression predicts distal metastases and poorer survival for breast cancer
    H Mao
    Department of Pathology, Henry Ford Health System, Detroit, MI 48202, USA
    Int J Oncol 18:587-91. 2001

Collaborators

  • H B Muss
  • D A Berry
  • L Norton
  • Maria Worsham
  • H L Parnes
  • J Aisner
  • H Mao
  • E M Sotomayor
  • C Cirrincione
  • M C Perry
  • S L Allen
  • M R Cooper
  • I C Henderson
  • T P Szatrowski
  • E Chuang
  • D B Duggan
  • H Liu
  • I Borrello
  • H I Levitsky
  • F M Rattis
  • X Fu
  • Z Fang
  • A G Cuenca
  • D Budman
  • M Perry
  • L Panasci
  • J Holland
  • M Citron
  • M Perloff

Detail Information

Publications5

  1. ncbi request reprint Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741
    J Abrams
    University of Maryland Cancer Center, Baltimore, MD, USA
    J Clin Oncol 17:64-73. 1999
    ..To investigate whether dose escalation of megestrol acetate (MA) improves response rate and survival in comparison with standard doses of MA...
  2. ncbi request reprint Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140
    H L Parnes
    Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, 6130 Executive Plaza EPN Room 2100, Rockville MD 20852, USA
    J Clin Oncol 21:1819-24. 2003
    ..To determine whether biochemical modulation with LV (leucovorin) enhances the efficacy of CAF (cyclophosphamide, doxorubicin, and fluorouracil) against metastatic breast cancer...
  3. ncbi request reprint Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281
    J Aisner
    University of Maryland Cancer Center, Baltimore, USA
    J Clin Oncol 13:1443-52. 1995
    ..We sought to compare three doxorubicin-based therapies for metastatic breast cancer for response frequency, time to treatment failure (TTF), and survival...
  4. ncbi request reprint Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression
    E M Sotomayor
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Blood 98:1070-7. 2001
    ..The intrinsic APC capacity of tumor cells has therefore little influence over T-cell priming versus tolerance, a decision that is regulated at the level of host APCs. (Blood. 2001;98:1070-1077)..
  5. ncbi request reprint Loss of nm23 expression predicts distal metastases and poorer survival for breast cancer
    H Mao
    Department of Pathology, Henry Ford Health System, Detroit, MI 48202, USA
    Int J Oncol 18:587-91. 2001
    ..Low nm23 expression is predictive of distal metastases and appears to be a risk factor that is independent of the presence or absence of positive axillary nodes at diagnosis...